"Designer drugs"--a current perspective.
D A Jerrard
Journal of Emergency Medicine 1990 DOI: 10.1016/0736-4679(90)90288-7 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Key findings | The authors argue that clandestine chemists modified existing controlled substances into new derivatives that, until 1986, temporarily escaped the Federal Controlled Substances Act because of their novel chemical structures, and that unsuspecting users continue to take these drugs recreationally. The article reviews the history, pharmacokinetics, treatment, and abuse trends of these "Designer Drugs." |
Abstract
Since the late 1970s, in an effort to quench the ever burgeoning appetite for pharmacological substances of abuse and to satiate their own need for profit, unscrupulous chemists have set up clandestine laboratories to produce and market new drugs for street sale. Using fairly common industrial chemicals, they have altered or modified preexisting controlled substances such as fentanyl, meperidine, mescaline, amphetamine, and phencyclidine, producing derivatives of these parent compounds that, up until 1986, were able to temporarily elude the guidelines of the Federal Controlled Substances Act due to their new and unique chemical structures. Unsuspecting users continue to use the drugs recreationally. This article will present a comprehensive review of these "Designer Drugs" looking at historical data, pharmacokinetics, treatment, abuse trends, and some of the more recent additions to the social pharmacopoeia.
Citations in the library
Cited by 4
- Designer drugs: mechanism of action and adverse effects Archives of Toxicology April 1, 2020
- Instability of the ecstasy market and a new kid on the block: mephedrone Journal of Psychopharmacology September 8, 2010
- Use and abuse of dissociative and psychedelic drugs in adolescence Pharmacology, Biochemistry, and Behavior January 27, 2021
- Methylenedioxymethamphetamine (MDMA, “Ecstasy”) Pediatric Emergency Care October 1, 2000
Cites 11
- Medical Toxicology: Diagnosis and Treatment of Human Poisoning. Annals of Internal Medicine March 1, 1988
- Subjective Reports of the Effects of MDMA in a Clinical Setting Journal of Psychoactive Drugs October 1, 1986
- Hallucinogenic Amphetamine Selectively Destroys Brain Serotonin Nerve Terminals Science September 6, 1985
- 'Eve' and 'Ecstasy'. A report of five deaths associated with the use of MDEA and MDMA JAMA March 27, 1987
- (±3,4-Methylenedioxymethamphetamine Selectively Damages Central Serotonergic Neurons in Nonhuman Primates JAMA July 1, 1988
and 6 more in the library